Trial reportBlood2016
Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease.
Trial report in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration.Haematologica · 2025Review
- Recent advances in therapeutic strategies of Erdheim-Chester disease.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Orbital histiocytosis; From A to Z.International ophthalmology · 2024Review
- Case report: Targeted treatment strategies for Erdheim-Chester disease.Frontiers in oncology · 2024Article
- Erdheim-Chester disease: A multisystem disease case illustration with rare manifestations and treatment challenges.Clinical case reports · 2023Article
- Extensive Aortic Thromboembolism in a Patient With Erdheim-Chester Disease: A Case Report.Frontiers in cardiovascular medicine · 2022Article
- Histiocytic disorders.Nature reviews. Disease primers · 2021Review
- Histiocytosis.Lancet (London, England) · 2021Review
- Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.Hematology. American Society of Hematology. Education Program · 2020Article
- Erdheim-Chester disease: a rapidly evolving disease model.Leukemia · 2020Review
- Clinical presentation, imaging and response to interferon-alpha therapy in Erdheim-Chester disease: case-based review.Rheumatology international · 2020Review
- Neurological manifestations of Erdheim-Chester Disease.Annals of clinical and translational neurology · 2020Article
- Erdheim-Chester Disease: a Concise Review.Current rheumatology reports · 2019Review
- Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.Current oncology reports · 2019Review
- Erdheim-Chester Disease Involving Lymph Nodes and Liver Clinically Mimicking Lymphoma: A Case Report.Journal of pathology and translational medicine · 2018Article
- An unusual case of interstitial lung disease in a patient with cardiopulmonary syndrome as the initial presentation of Erdheim-Chester disease.BMJ case reports · 2017Article
- Article
- Erdheim-Chester disease BRAF (-) Diagnosis through cutaneous manifestations and good response with anakinra treatment.Anais brasileiros de dermatologiaArticle
- Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.OncoimmunologyArticle
- Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy.Neuro-oncology advancesArticle
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26847247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.